Lutetium-177-PSMA (Lu-177-PSMA) is a targeted internal radiation therapy designed for metastatic prostate cancer. It uses a radioactive drug to precisely locate and destroy cancer cells while sparing most healthy tissue. This treatment offers new hope for patients with metastatic prostate cancer, including those who have not responded well to androgen treatment, chemotherapy or newer hormonal medications.

Advantages: 

• Precisely eliminate prostate cancer cells while sparing most healthy tissues in patients 
• Minimising the chance of radiation damage to surrounding organs 
• Side effects are generally mild and short-lived 

Candidates for Lu-177-PSMA Therapy: 

• Advanced metastatic prostate cancer patients, especially those who have seen limited results from androgen treatment, chemotherapy or newer hormonal medications 
• Patients who have been assessed with the use of imaging to confirm radionuclide binding 
• Patients are recommended to undergo assessments by our specialists to determine their suitability